Benralizumab at 20 mg and 100 mg doses seemed to reduce asthma exacerbations in adults with uncontrolled eosinophilic asthma and baseline blood eosinophils of at least 300 cells per L , possibly due to targeting of the interleukin 5 receptor rather than interleukin 5 ligand .